[Música] Hola, buenos días a todos. Voy a empezar haciéndoles una pregunta muy sencilla, sin trampa, y les invito a que levanten la mano si saben la respuesta. ¿Cuántos de ustedes reconocen, no saben dónde está este lugar? Como saben, es el Museo del Lubre en París, este museo mundialmente conocido y visitado por 9 millones de personas al año. Y ahora, ¿cuántos de ustedes han visto alguna vez o reconocen este cuadro? La Yoconda de Leonardo da Vinci, también un cuadro que ha dado lugar a muchas historias fic ...

[Música] No sé si os ha pasado que cuando llega el verano, sobre todo la última semana, las últimas semanas, y veis la fecha de de la reincorporación al curro, empiezais a decir, "Volver a ver a ese jefe con el que me llevo regular o esos compañeros o o trabajar en esa empresa o o incluso en esa profesión, me empieza a dar pereza. Bueno, eh, que sepáis que que no sois los únicos si os pasa, ¿vale. Le pasa mucha gente, a mí me ha pasado y de hecho, eh, por esas fechas, más o menos finales de de las típicas v ...

Mariah Carey’s Christmas Classic Becomes A Bestseller Again — In July https://t.co/heyfKJn6l3 https://t.co/ll6vLxgrbC ...

Music Therapy & Neurodiversity - Music serves as a powerful medium to connect with disadvantaged communities, especially neurodiverse individuals including those with autism spectrum disorder, ADHD, and chromosomal abnormalities [2] - Music-based interventions are rooted in Indian classical music, leveraging its ancient wisdom [4][5] - Music stimulates multiple brain regions simultaneously, regardless of active or passive engagement [8] - Music is multi-sensory, engaging kinesthetic, auditory, visual, and tactile systems [12][13] - Individuals may have sensory sensitivities to elements of music like sound, pitch, or instruments [16] - Music perception involves sound, tone, emotion, and language [17][18] - Music can be broken down into elements to aid understanding for individuals with sensory sensitivities [15] Application & Benefits - Music therapy can help individuals discriminate between sound, music, and noise [20] - Music can be collaborated with disciplines of psychology and neuroscience [26] - Music can be used as a healing agent and a wholesome exercise to relieve stress [30] - Music therapy is about empathizing and gathering insight into someone else's mind to fix a problem [32][33]

Why dressing up is now an essential part of the live music experience https://t.co/zveXreVp5S ...

SAN DIEGO, July 15, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced results from a new analysis using real-world data from CAHtalog®, a comprehensive registry of patients with classic congenital adrenal hyperplasia in the United States. The analysis demonstrated significant variability in glucocorticoid treatment regimens and frequent changes in health status and outcomes over time in both pediatric and adult patients. These results were presented at the Endocrine Society's ...

Core Viewpoint - JS Foundry, a Japanese wafer foundry, filed for bankruptcy after failed negotiations for SiC technology collaboration, despite initial government support and a brief operational history [1][2][3]. Group 1: Company Background - JS Foundry was established in 2022 and operates a 41-year-old wafer plant previously owned by Sanyo and later by ON Semiconductor [3]. - The company had a revenue of $68 million in its first operational year, a significant increase from $17.6 million the previous year [3]. - JS Foundry has a debt of $110 million and employed 550 staff members [3][4]. Group 2: Market Context - The power semiconductor market is facing challenges due to a slowdown in electric vehicle sales and increased competition from China [4]. - Notable competitors, such as Wolfspeed, have also filed for bankruptcy, and Renesas Electronics has abandoned plans to start SiC production later this year [4]. Group 3: Government Support and Investment - The Japanese central government and Niigata Prefecture planned to provide subsidies worth billions of yen for equipment investment in JS Foundry [4]. - The company was co-founded by Mercuria Investment and Sangyo Sosei Advisory, backed by the Development Bank of Japan [3][4].

Core Insights - PROCEPT BioRobotics Corporation announced that Aquablation therapy has been assigned a Category I CPT code effective January 1, 2026, marking a significant milestone for the company and the urology community [1][3] - The new Category I CPT code 52XX1 will replace the previous Category III CPT code 0421T and is associated with a proposed national average payment of approximately $540 under the 2026 Medicare Physician Fee Schedule [2][3] - The transition to a Category I code is expected to enhance surgeon adoption and increase patient access to Aquablation therapy, which offers durable symptom relief with a low risk of sexual side effects [3] Payment Structure - The 2026 proposed payment for Aquablation therapy is set at 16.14 total RVUs, compared to 15.82 total RVUs for TURP, which translates to an average payment of approximately $529 [3] - The Proposed Physician Fee Schedule was released on July 14, 2025, and will undergo a public comment period until September 2025, with a final rule expected in November 2025 [4] Aquablation Therapy Overview - Aquablation therapy is the first and only ultrasound-guided, robotic-assisted, heat-free waterjet treatment for benign prostatic hyperplasia (BPH), providing personalized treatment planning based on real-time imaging [5][6] - The technology allows for precise removal of prostate tissue while preserving critical anatomy related to erectile and ejaculatory function, making it suitable for a wide range of patients [5][6] - BPH affects approximately 40 million men in the United States, highlighting the significant market potential for Aquablation therapy [6]

Blockchain ability to rebrand things will be studied for millennia https://t.co/Ks9YW4ha1Wjesse.base.eth (@jessepollak):songcoins are the next step for music coming onchain ...

Core Insights - Neurocrine Biosciences presented new data from the Phase 3 CAHtalyst studies showing that CRENESSITY® (crinecerfont) leads to significant improvements in weight-related outcomes for patients with classic congenital adrenal hyperplasia (CAH) [1][2][5] Group 1: Study Overview - The Phase 3 CAHtalyst program is the largest interventional clinical trial for classic CAH, involving 285 patients (103 pediatric and 182 adult) [2][12] - The studies included a double-blind, placebo-controlled period followed by an open-label period where all patients received CRENESSITY [2][12] Group 2: Weight-Related Outcomes - Adult patients treated with CRENESSITY showed a mean BMI reduction of 0.8 kg/m² compared to a 0.4 kg/m² reduction in the placebo group at Month 12 [4][6] - 39% of adult patients on CRENESSITY achieved over a 5% weight reduction, compared to 14% in the placebo group [4][6] - Pediatric patients on CRENESSITY maintained reductions in BMI standard deviation scores (SDS) through Week 52, while those on placebo saw an increase [6][4] Group 3: Insulin Resistance Improvements - Significant reductions in insulin resistance were observed in both adult and pediatric patients treated with CRENESSITY compared to placebo [5][6] - The mean HOMA-IR score decreased more significantly in the CRENESSITY group than in the placebo group [6][7] Group 4: Safety Profile - CRENESSITY demonstrated a favorable safety profile, with common side effects being mild to moderate and not leading to discontinuation of the drug [8][20] - Common side effects in children included headache and stomach pain, while adults reported fatigue and headache [8][22] Group 5: Regulatory and Market Context - Data from the CAHtalyst studies supported the FDA approval of CRENESSITY in December 2024 [15] - CRENESSITY is positioned to evolve the standard of care for classic CAH by allowing for reduced glucocorticoid doses while maintaining or improving androgen control [2][16]